36 results about "Iontophoresis therapy" patented technology

This invention relates to methods for reducing the presence of a compound in an ionically conductive material, e.g., for use in iontophoretic devices, wherein the presence of the compound interferes with detecting a selected analyte. Removal of the compound can typically take place either during or after the manufacture of the ionically conductive material or an assembly comprising this material. Also disclosed are methods for generating selectively permeable barriers on the reactive faces of electrodes. Further, this invention relates to hydrogels comprising one or more biocides, as well as assemblies containing such hydrogels.

Cosmetic facial treatment delivery system with skincare benefit agents and iontophoresis micro-current zones are provided for delivering skincare treatments to multiple targeted areas of the skin to treat different concerns of an individual user. The system includes a sheet substrate with skincare agents and a micro-current generator secured to the sheet. The micro-current generator includes an oxidation agent, a reduction agent and a hydrogel with salt. The generator is activated by wetting to produce micro-current. The sheet is applied to skin. The micro-current generated facilitates delivery of skin benefit agents from the sheet by iontophoresis, or directly affects treatment by delivery of iontophoresis micro-current to the skin.

The present disclosure relates to an iontophoretic device. In one aspect, the device includes a barrier layer between the drug reservoir and wearer. In another aspect, the device includes a counterelectrode opposite the driving electrode relative to the drug reservoir.

An iontophoretic drug delivery device storage apparatus and a method of using that device is disclosed. The device comprises a fluid reservoir, an electrode assembly and a tray apparatus. The fluid reservoir is capable of retaining a medicament and has a sealed fluid chamber defined by at least one seal. The seal includes a weaker region and a pinch-like configuration associated with that region such that application of pressure to the fluid reservoir breaks the weaker region of the seal, releasing the retained medicament. The electrode assembly comprises an active electrode, at least two passive electrodes a medicament carrying region, and a moat region around the medicament carrying region so that once fluid is delivered from the fluid reservoir to the electrode assembly the fluid is substantially retained in the medicament carrying means.

Embodiments of the invention provide methods for the transdermal delivery of therapeutic agents for the treatment of addictive cravings e.g., from nicotine. An embodiment of a method for such delivery comprises positioning at least one electrode assembly in electrical communication with a patient's skin. The assembly includes a solution comprising a therapeutic agent which passively diffuses into skin. A dose of agent is delivered from the assembly into skin during a first period using a first current having a characteristic e.g., polarity and magnitude, to repel agent out of the assembly. During a second period, a second current having a characteristic to attract agent is used to retain agent in the assembly such that delivery of agent into skin is minimized. In particular embodiments, a dose of agent may be delivered on-demand using an input from the patient using an inhalation sensing device which mimics an inhaled form of tobacco.

By using a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/l, the composition having a pH of 4 to 6.5 in a iontophoretic device for the treatment of Parkinson's disease, it became possible to obtain a rotigotine flux across the human stratum corneum which was higher than the one previously obtained with conventional passive diffusion systems.

The present invention provides a method of preparing a hydrophilic pressure sensitive adhesive (PSA) composition which enables the preparation of an adhesive having a specific optimal degree of adhesion. The hydrophilic PSA comprises a hydrophilic polymer and a complementary short-chain plasticizer, wherein the hydrophilic polymer and plasticizer are capable of hydrogen bonding or electrostatic bonding to each other in proportions such that the The main properties of the adhesive composition such as cohesive strength, cohesive strength and hydrophilicity are optimized. The adhesives have a wide variety of uses, for example, as biomedical adhesives, applied to the skin or other body surfaces, whereby they can be used in various drug delivery method areas (e.g., topical, transdermal, transmucosal, ionic electroosmosis), medical skin (dressing) coverings and wound healing products and biomedical electrodes.

An comprising (A) a working electrode structure being equipped with a working electrode, an ion-exchange membrane and a medicine-containing portion which contains an ionic medicine, (B) a counter electrode structure being equipped with an electrode opposing said working electrode and (C) a power source unit electrically connected to the working electrode structure and to the counter electrode structure, said ionic medicine being permeated into a living body by the electrophoresis through the ion-exchange membrane; wherein said ion-exchange membrane has, as an ion-exchange resin, a crosslinked (meth)acrylic resin having a (meth)acrylic structural unit A to which an ion-exchange group is bonded. The iontophoresis device using the above ion-exchange membrane is capable of efficiently administering ionic medicines having ionic formula weights of not smaller than 500 into the living body.

Methods, systems and other embodiments associated with administering ionotophoretic medicines are presented. A method of administering ionotophoretic medicines includes applying a voltage across a body tissue and an iontophoretic solution including medicine. At least some of the iontophoretic solution including medicine is then injected into the body tissue without requiring the iontophoretic transportation of the iontophoretic solution including medicine through the skin. The iontophoretic solution is typically injected while the voltage is applied. The voltage causes an ionic current of iontophoretic medicine to flow which disperses the medicine within the body tissue toward body tissue connected to the voltage.

Provided is a smart contact lens for non-invasive drug delivery including a platform configured to be worn on an eye, a reservoir installed within the platform, and having a receiving part in which a drug is received, to provide the eye with the drug, an electrode for iontophoresis installed in the reservoir to make iontophoresis work, to provide the eye with the drug from the reservoir, and an activation chip electrically connected to the electrode for iontophoresis to activate iontophoresis.

The invention relates to a transdermal therapeutic system (TTS) for delivering pharmaceutical active ingredients. The TTS includes a cover layer and at least one active-ingredient-containing carrier material. At least one retaining element is located between the active-ingredient-containing carrier material and the cover layer, with the retaining element fixing the active-ingredient-containing carrier material onto the cover layer. The invention further relates to a method for fastening an active-ingredient-containing carrier material to a cover layer of a TTS in the presence of hook-and-loop strip segments and the use of a hook-and-loop strip in transdermal or iontophoretic administration of pharmaceutical or therapeutic active ingredients to patients.

The invention relates to an iontophoresis device adopting an efficient environment-friendly biocompatible ion battery, in particular to an efficient environment-friendly biocompatible iontophoresis device driven by a reverse electrodialysis ion battery, which is made of substances, such as sediments, gas or non-ionidizable substances in water solution, formed through a reaction..

An embodiment relates to a transdermal drug delivery system comprising a patch comprising a) a cartridge comprising a drug; b) a bio-sensor and a non bio-sensor; c) an active delivery pad comprising an electrode for delivery of the drug into a tissue via iontophoresis; d) a power source of electrical energy connected to the electrode; e) a microcontroller configured to control a release of the drug wherein the patch is attached to the tissue via an adhesive pad, and optionally top of patch is covered with a sheet; wherein the bio-sensor is configured to detect a physiological parameter; wherein the non bio-sensor is configured with a software to control working of the patch.

The invention relates to the technical field of conditioning liquid medicine, and discloses an aromatic external conditioning liquid medicine. The liquid medicine comprises, by weight, 35% of ice table essential oil, 5% of ginger root oil, 5% of frankincense oil, 5% of fennel oil, 2% of myrrh oil, 1% of rosemary leaf oil, 2% of camphor ice, 5% of cinnamon oil, 3% of corn blank oil, 15% of semen brassicae essential oil, 2% of safflower essential oil, 5% of garden balsam seed essential oil, 1% of clove essential oil, 2% of white radish seed oil, 2% of camphor stock solution, 5% of chamomile essential oil, 2% of fructus psoraleae extract and 3% of lycopodium clavatum extract. According to the formula and the preparation process of the aromatic external conditioning liquid medicine, all the compositions are scientific in compatibility, fine in medicine selection, mild in medicine property and free of toxic and side effects, the liquid medicine is the aromatic liquid medicine, the disadvantage that external liquid medicine is too heavy in traditional Chinese medicine taste and too heavy in alcohol taste is thoroughly broken through, and the liquid medicine adopts a medicine iontophoresis therapy to achieve local administration, skin permeation, bone permeation absorption and focus action, so the effect is better and more stable, and the effect taking speed is higher.

The present invention relates to frigostable compositions suitable for iontophoretic transdermal delivery of a triptan compound. The inventive compositions include a salt of a triptan compound, preferably sumatriptan succinate, a polyamine, a dicarboxylic acid, and water or an aqueous solvent mixture, with the composition being free of monocarboxylic acids. The invention further relates to the use of the composition as an integral component of an iontophoretic patch, preferably as an anodic reservoir of the patch.